|Articles|May 1, 2003

Pharmaceutical Technology Europe

  • Pharmaceutical Technology Europe-05-01-2003
  • Volume 15
  • Issue 5

Qualification of a Chromotographic Column

In this article, five industry experts share their insights to ensure that your column qualification protocols can survive the increased scrutiny of FDA inspectors.

The US Food and Drug Administration (FDA) has become more knowledgeable regarding process chromatography - and more demanding concerning column qualification. In this article, five industry experts share their insights on how to qualify a chromatographic column. Their advice: write unambiguous standard operating procedures (SOPs); focus on the reproducibility of column packing; choose appropriate metrics; and analyse your testing procedures to reduce the chance of erroneous results.

This article is currently available in printed form only.
To ensure access to all articles from every issue of Pharmaceutical Technology Europesubscribe here now.

Articles in this issue

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.